Viability of the biochar production from different manure wastes in the Amblés Valley (Ávila, Spain)

In the last years, intensive animal husbandry production has led to a large concentration of animals in small areas. This has resulted in the production of excessive amounts of manures with insufficient nearby land for application. One of this areas is the Amblés Valley located in the centre of Spain, near to Ávila city, with an extension of 167472 ha of which 88.9% is agricultural land. This valley has an important livestock focused on pig, cattle, chicken production which is associated with the generation of more than 200,000 t/year of manure. There are a number of environmental problems associated with these intensive agricultural systems, including N and P pollution of water bodies, methane emissions and odour pollution. These serious environmental threats are called for innovative environmental management approaches. A feasible technology for the management of manures, offering a potential to valorise these wastes, is pyrolysis, which results in the production of biochar. The objective of this work is evaluated the technical and economic feasibility of the production of biochar in Amblés Valley (Spain)

Evidence of Sea Level Rise At the Peruvian Coast (1942-2019)

The present work aims to analyze the variability of the sea level of the Peruvian coast with time series over a long observation period (Seventy-eight years, from 1942 to 2019). Data came from the Talara, Callao and Matarani tide gauge stations located at the north, center and south of the coast. Variations of sea level as well as air and seawater surface temperature were analyzed. Among the different scenarios studied, a sea level rise of 6.79, 4.21 and 5.16 mm/year for Talara, Callao and Matarani, respectively was found during the 1979–1997 nodal cycle. However, these results decreased significantly during the next cycle (1998–2016) until values of 1.53, 2.16 and 1.0 mm/year for Talara, Callao and Matarani, respectively. Thus, it has been demonstrated that sea level rise are highly dependent on the time interval chosen. Moreover, large interannual changes of up to 200 mm/year are observed, due to recurring phenomena, such as “El Niño”. On the other hand, the trends obtained are slightly lower than those shown by the IPCC up until 2006 but significantly higher values have been observed. Finally, the results presented herein show the necessity of a local study of the sea level variability at the coastal areas

Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.

BACKGROUND: Multiple sclerosis (MS) is a progressively debilitating neurological condition in which the immune system abnormally erodes the myelin sheath insulating the nerves. Mesenchymal stem cells (MSC) have been used in the last decade to safely treat certain immune and inflammatory conditions. METHODS: A safety and feasibility study was completed on the use of umbilical cord MSC (UCMSC) as a treatment for MS. In this 1-year study, consenting subjects received seven intravenous infusions of 20 × 10 RESULTS: Twenty subjects were enrolled in this study. No serious adverse events were reported. Of the mild AEs denoted as possibly related to treatment, most were headache or fatigue. Symptom improvements were most notable 1 month after treatment. Improvements were seen in EDSS scores (p \u3c 0.03), as well as in bladder, bowel, and sexual dysfunction (p \u3c 0.01), in non-dominant hand average scores (p \u3c 0.01), in walk times (p \u3c 0.02) and general perspective of a positive health change and improved quality of life. MRI scans of the brain and the cervical spinal cord showed inactive lesions in 15/18 (83.3%) subjects after 1 year. CONCLUSIONS: Treatment with UCMSC intravenous infusions for subjects with MS is safe, and potential therapeutic benefits should be further investigated. Trial registration ClinicalTrials.gov NCT02034188. Registered Jan 13, 2014. https://clinicaltrials.gov/ct2/show/NCT02034188

Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach

Combination stem cell therapy for heart failure

Patients with congestive heart failure (CHF) that are not eligible for transplantation have limited therapeutic options. Stem cell therapy such as autologous bone marrow, mobilized peripheral blood, or purified cells thereof has been used clinically since 2001. To date over 1000 patients have received cellular therapy as part of randomized trials, with the general consensus being that a moderate but statistically significant benefit occurs. Therefore, one of the important next steps in the field is optimization. In this paper we discuss three ways to approach this issue: a) increasing stem cell migration to the heart; b) augmenting stem cell activity; and c) combining existing stem cell therapies to recapitulate a "therapeutic niche". We conclude by describing a case report of a heart failure patient treated with a combination stem cell protocol in an attempt to augment beneficial aspects of cord blood CD34 cells and mesenchymal-like stem cells

IFNL3 rs12980275 Polymorphism Predicts Septic Shock-Related Death in Patients Undergoing Major Surgery: A Retrospective Study

Interferon lambda 3 (IFNL3, previously called IL-28B) is a cytokine with effects against viral and bacterial pathogens. We aimed to analyze the IFNL3 rs12980275 SNP in patients who underwent major surgery, in order to establish its relationship with susceptibility to septic shock and septic shock-related death in these patients. We performed a case-control study on 376 patients to establish the association between IFNL3 rs12980275 SNP and the susceptibility to develop septic shock. Besides, we performed a longitudinal study among 172 septic shock patients using survival analysis with one censoring point of 28-days mortality. The IFNL3 rs12980275 polymorphism was genotyped by Agena Bioscience's MassARRAY platform. IFNL3 rs12980275 polymorphism was not associated with higher susceptibility to infection and septic shock development. Regarding survival analysis, the Kaplan-Meier analysis showed that patients with IFNL3 rs12980275 AA genotype had higher survival than patients with GG genotype (p = 0.003). The Cox regression analysis adjusted by the most relevant clinical and epidemiological characteristics showed that the GG genotype (recessive model) and the presence of the G allele (additive model) were associated with higher risk of death [adjusted hazard ratio (aHR) = 2.15, p = 0.034; aHR = 1.50, p = 0.030, respectively]. In conclusion, IFNL3 rs12980275 polymorphism was associated with septic shock-related death in patients who underwent major surgery. The A allele was linked to protection, and the G allele was associated with an increased risk of death. This is a first preliminary study that suggests for the first time a role of IFNL3 polymorphisms in the prognosis of septic shock.This work has been supported by grants given by Instituto de Salud Carlos III (grant numbers PI15/01451 to ET), Gerencia de Salud, Consejería de Sanidad, Junta de Castilla y Leon (grant number GRS 463/A/10 and 773/A/13 to ET), and PFIZER (grant number CT25-ESP01-01 to SR). MJ-S and AF-R are supported by Instituto de Salud Carlos III (grant numbers CP17CIII/00007 and CP14CIII/00010, respectively).S

Supply Chain Management y Logística en la Industria de Flores en Colombia

El “Supply chain" como método de aplicación transversal a diferentes empresas productivas o de servicio ofrece alternativas viables que fortalezcan la industria de flores de Colombia para lo cual se realiza la caracterización del estado actual del mercado colombiano en este aspecto, y el nivel competitivo de las empresas nacionales. Aunque la industria de las flores en Colombia ha trascendido a nivel mundial por ser una de las industrias con más fuerza del país gracias a la calidad de su producto favorecida por las condiciones climatológicas y topográficas del territorio, Sin embargo en comparación con otros países productores de flores su participación en el mercado es limitada, y la importancia del "Supply chain" se evidencia en casos como el de Holanda, que con tierras no tan fértiles para el cultivo de flores, sea el país número uno en exportación con más del 50% de participación en el mercado. En nuestro trabajo tomamos en cuenta el estado actual del mercado de flores en Colombia, tomando sus aspectos positivos y negativos en los cuales se realiza un análisis sobre las competencias logísticas de nuestro país en cuanto a la producción, mercados mundiales, comercialización y factores de competitividad en comparación con el país de mayor participación en el mercado internacional. Dado que la industria de floricultores colombianos se ha convertido en el segundo rubro no tradicional de exportación, por lo cual la cadena de distribución varía de acuerdo al mercado en cuanto a la incursión de multinacionales en la distribución de flores frescas hacia Estados Unidos, esto podría acrecentar las exportaciones colombianas a ese mercado, aunque Colombia cuenta con todas las ventajas naturales óptimas para la producción de flores. Y en cuanto a costos ha perdido competitividad, ya que otros países están haciendo lo mismo, pero más eficiente; con base a esto debe haber un cambio radical los floricultores colombianos deben dejar de ser una industria exportadora y convertirse en una globalizada.The supply chain as a method of transversal application for companies such as productive or service that offers viable alternatives that strengthen flowers’ Industries in Colombia, the characterization of the current state of the Colombian market in this aspect is made, and the competitive level of national companies is also crucial. Although the flowers’ industry in Colombia has transcended worldwide because it is one of the strongest industries in the country thanks to the quality of its product favored by the climatic and topographic conditions of the territory, however in comparison with others exporting flowers’ countries, Colombia its share in the market is limited. The importance of the "Supply chain" is evidenced in cases such as Netherlands, which with land not so fertile for the cultivation of flowers, is the number one export country with more than 50% market share. In this assessment, we put in consideration the current state of the flower market in Colombia, also getting its positive and negative aspects, the analysis is made of the logistics capabilities of our country in terms of production, global markets, marketing and competitiveness factors compared to the country with the largest share in the international market. Generally speaking, the flowers’ industry in Colombia has become the second non-traditional export sector, which is why the distribution chain varies according to the market in terms of the incursion of multinationals in the distribution of “fresh flowers” to the United States, this could increase Colombian exports to that market, although Colombia has all the optimal natural advantages for increasing flowers’ production. And in terms of costs, it has lost competitiveness, since other countries are doing the same, but more efficient. In other words, there must be a radical change. Colombian flowers growers must stop being an export industry and become a globalized one

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

The stromal vascular fraction (SVF) of adipose tissue is known to contain mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, preadipocytes, as well as anti-inflammatory M2 macrophages. Safety of autologous adipose tissue implantation is supported by extensive use of this procedure in cosmetic surgery, as well as by ongoing studies using in vitro expanded adipose derived MSC. Equine and canine studies demonstrating anti-inflammatory and regenerative effects of non-expanded SVF cells have yielded promising results. Although non-expanded SVF cells have been used successfully in accelerating healing of Crohn's fistulas, to our knowledge clinical use of these cells for systemic immune modulation has not been reported. In this communication we discuss the rationale for use of autologous SVF in treatment of multiple sclerosis and describe our experiences with three patients. Based on this rationale and initial experiences, we propose controlled trials of autologous SVF in various inflammatory conditions

Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report

Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI